253 related articles for article (PubMed ID: 30352576)
1. Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma.
Jacinto AA; Batalha Filho ES; Viana LS; De Marchi P; Capuzzo RC; Gama RR; Boldrini Junior D; Santos CR; Pinto GDJ; Dias JM; Canton HP; Carvalho R; Radicchi LA; Bentzen S; Zubizarreta E; Carvalho AL
BMC Cancer; 2018 Oct; 18(1):1026. PubMed ID: 30352576
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results.
Zenda S; Onozawa Y; Tahara M; Kawashima M; Shikama N; Sasaki S; Boku N
Jpn J Clin Oncol; 2007 Oct; 37(10):725-9. PubMed ID: 17925299
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
Tsao AS; Garden AS; Kies MS; Morrison W; Feng L; Lee JJ; Khuri F; Zinner R; Myers J; Papadimitrakopoulou V; Lewin J; Clayman GL; Ang KK; Glisson BS
J Clin Oncol; 2006 Sep; 24(25):4163-9. PubMed ID: 16943532
[TBL] [Abstract][Full Text] [Related]
6. Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.
Wibault P; Bensmaine MA; de Forni M; Armand JP; Tellez Bernal E; Guillot T; Recondo G; Domenge C; Janot F; Borel C; Luboinski B; Eschwege F; Cvitkovic E
J Clin Oncol; 1996 Apr; 14(4):1192-200. PubMed ID: 8648374
[TBL] [Abstract][Full Text] [Related]
7. Definitive altered fractionation radiotherapy and concomitant weekly cisplatin for locally advanced head and neck cancer.
Boulmay BC; Chera BS; Morris CG; Kirwan J; Riggs CE; Lawson M; Mendenhall WM
Am J Clin Oncol; 2009 Oct; 32(5):488-91. PubMed ID: 19528791
[TBL] [Abstract][Full Text] [Related]
8. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Kohno N; Kitahara S; Tamura E; Tanabe T
Oncology; 2002; 63(3):226-31. PubMed ID: 12381901
[TBL] [Abstract][Full Text] [Related]
9. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
12. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma.
de Castro G; Snitcovsky IM; Gebrim EM; Leitão GM; Nadalin W; Ferraz AR; Federico MH
Eur Arch Otorhinolaryngol; 2007 Dec; 264(12):1475-82. PubMed ID: 17643256
[TBL] [Abstract][Full Text] [Related]
13. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Bourhis J; Sire C; Graff P; Grégoire V; Maingon P; Calais G; Gery B; Martin L; Alfonsi M; Desprez P; Pignon T; Bardet E; Rives M; Geoffrois L; Daly-Schveitzer N; Sen S; Tuchais C; Dupuis O; Guerif S; Lapeyre M; Favrel V; Hamoir M; Lusinchi A; Temam S; Pinna A; Tao YG; Blanchard P; Aupérin A
Lancet Oncol; 2012 Feb; 13(2):145-53. PubMed ID: 22261362
[TBL] [Abstract][Full Text] [Related]
14. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
[TBL] [Abstract][Full Text] [Related]
15. Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Recchia F; Saggio G; Cesta A; Amiconi G; di Blasio A; Candeloro G; Valeriani M; Tombolini V; Rea S
Anticancer Res; 2006; 26(3B):2317-24. PubMed ID: 16821609
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.
Wendt TG; Grabenbauer GG; Rödel CM; Thiel HJ; Aydin H; Rohloff R; Wustrow TP; Iro H; Popella C; Schalhorn A
J Clin Oncol; 1998 Apr; 16(4):1318-24. PubMed ID: 9552032
[TBL] [Abstract][Full Text] [Related]
18. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer.
Chen C; Kane M; Song J; Campana J; Raben A; Hu K; Harrison L; Quon H; Dancey J; Baron A; Said S; Eckhardt SG; Raben D
J Clin Oncol; 2007 Nov; 25(31):4880-6. PubMed ID: 17971583
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
